Daily Cosmetic Research Analysis
Three studies advance aesthetic and reconstructive care: a PRISMA-compliant systematic review synthesizes early evidence that microcoring improves skin quality with acceptable safety; a randomized trial shows a prebiotic/panthenol dermocosmetic significantly accelerates healing and cosmetic outcomes after cryotherapy for actinic keratoses; and a long-term cohort analysis supports the oncologic safety of volume-replacement oncoplastic breast surgery with better margin status and fewer secondary p
Summary
Three studies advance aesthetic and reconstructive care: a PRISMA-compliant systematic review synthesizes early evidence that microcoring improves skin quality with acceptable safety; a randomized trial shows a prebiotic/panthenol dermocosmetic significantly accelerates healing and cosmetic outcomes after cryotherapy for actinic keratoses; and a long-term cohort analysis supports the oncologic safety of volume-replacement oncoplastic breast surgery with better margin status and fewer secondary procedures.
Research Themes
- Minimally invasive skin rejuvenation technologies
- Adjunctive dermocosmetics to enhance post-procedural recovery
- Oncoplastic surgical strategies balancing oncologic and cosmetic outcomes
Selected Articles
1. Core Innovations in Skin Rejuvenation: A Systematic Review of Microcoring Technology.
This PRISMA-compliant systematic review identified 8 studies (3 preclinical porcine, 5 clinical; 112 patients) showing that microcoring improves facial rhytids and skin quality via tissue removal and dermal remodeling, with trace-to-moderate procedural pain/bleeding and transient postprocedure skin effects. The technology is promising but requires larger cohorts, longer follow-up, and head-to-head comparisons.
Impact: It synthesizes early clinical and preclinical evidence on a novel minimally invasive rejuvenation modality that may reshape non-surgical aesthetic practice.
Clinical Implications: Microcoring appears effective and tolerable for facial rejuvenation, but clinicians should counsel patients about transient effects and the immature evidence base; adoption should be within controlled protocols while awaiting larger controlled trials.
Key Findings
- Included 8 studies: 3 preclinical porcine and 5 clinical studies totaling 112 patients
- Demonstrated improvements in facial rhytids, skin tightening, and epidermal/dermal remodeling
- Adverse effects were generally trace-to-moderate pain/bleeding and transient postprocedure skin reactions
- Heterogeneous device parameters (needle size, depth, density) across studies
Methodological Strengths
- PRISMA-compliant systematic search and risk-of-bias assessment
- Integration of preclinical and clinical data to triangulate mechanisms and outcomes
Limitations
- Small clinical sample sizes with heterogeneous protocols and devices
- Limited follow-up durations and absence of head-to-head randomized comparisons
Future Directions: Conduct multicenter randomized controlled trials comparing microcoring with established minimally invasive modalities, standardize parameters, and incorporate long-term histology and patient-reported outcomes.
BACKGROUND: Microcoring is a novel, minimally invasive technology for skin rejuvenation that uses hollow needles to remove full-thickness skin cores. OBJECTIVE: To review the current evidence on the outcomes and safety of microcoring and identify areas for future research. PATIENTS AND METHODS/MATERIALS: A PRISMA-compliant systematic review was conducted using the search strategy "micro-coring' OR "microcoring" across PubMed, Embase, Web of Science, and Cochrane. Risk of bias and quality assessment were conducted. RESULTS: Eight studies were included: three preclinical in vivo porcine stud
2. Prebiotic- and Panthenol-Containing Multipurpose Healing Dermocosmetics Post-Cryotherapy for Actinic Keratoses: Results of a Randomized Controlled Trial.
In a randomized, unblinded trial of 75 AK patients post-cryotherapy, adding a prebiotic/panthenol dermocosmetic to standard boric acid soaks shortened median healing time by 4.5 days (7 vs 11.5; P<0.0005), increased excellent cosmetic outcomes (50% vs 20%), and reduced the severity of local skin reactions, with no reported adverse events.
Impact: Pragmatic randomized data support a simple, safe adjunct that accelerates recovery and improves cosmetic outcomes after a common dermatologic procedure.
Clinical Implications: Consider prescribing a prebiotic/panthenol dermocosmetic after AK cryotherapy to reduce downtime, improve cosmesis, and mitigate local reactions; integrate into postprocedural care pathways.
Key Findings
- Randomized 75 adults post-cryotherapy to BA alone vs BA plus prebiotic/panthenol dermocosmetic
- Healing time reduced by 4.5 days (median 7 vs 11.5 days; ~40% reduction; P<0.0005)
- Higher rate of excellent cosmetic outcomes in complete responders (50% vs 20%)
- Lower severity of local skin reactions (median 2 vs 3 at day 3; P<0.0001) and no reported adverse events
Methodological Strengths
- Randomized controlled design with clinically meaningful endpoints (healing time, cosmesis, LSR)
- Clear, statistically robust primary outcome with large effect size
Limitations
- Unblinded, single-center design may introduce performance and detection bias
- Short follow-up (30 days) limits assessment of longer-term recurrence or scarring
Future Directions: Validate in multicenter, blinded trials with longer follow-up, cost-effectiveness analysis, and standardized cosmetic assessment (e.g., blinded photo-grading, 3D imaging).
INTRODUCTION: Actinic keratosis (AKs) is a precancerous skin lesion that can progress to keratinocyte carcinoma. OBJECTIVE: The objective of the study was to evaluate the efficacy of a dermocosmetic (DC) formulation containing prebiotic active ingredients (Aqua Posae Filiformis, a complex made of ferments, sugars, plant extracts, panthenol, madecassoside, and zinc) on healing time and local skin reactions (LSR) following cryotherapy of AKs and to compare the application of DC and boric acid 3% solution soaks (BA) vs. BA alone. METHODS: Seventy-five adult patients presenting with a maximum of five isolated AKs on the face and/or scalp and who underwent cryotherapy (T0) were enrolled. Post-treatment, patients initiated the application of BA only or BA followed by DC once daily for 30 days (unblinded 1:1 randomization). The evaluation of efficacy in healing time and cosmetic outcomes was assessed 30 days post-treatment (T2); LSR was evaluated three days post-treatment (T1). RESULTS: There was a gain of 4.5 days (40%) in healing time in the BA+DC group compared to the BA group, with a median time of seven days versus 11.5 days (P <0.0005). Additionally, 50% of lesions in complete response had an excellent cosmetic outcome with BA+DC vs. 20% with BA only. The majority of patients treated with BA+DC had mild LSR vs. moderate LSR with BA, with a median value of two vs three, respectively (P <0.0001). CONCLUSION: The addition of a prebiotic DC significantly reduced healing time, improved cosmetic outcomes, and minimized LSR post-cryotherapy. No adverse event was reported with this treatment.
3. Cohort study comparing volume replacement oncoplastic breast surgery with standard wide local excision for breast cancer.
In a single-center retrospective cohort (VR-OPS n=79; WLE n=80), volume-replacement oncoplastic surgery achieved significantly more negative margins (RR 0.36; P=0.01) and reduced need for symmetrization surgery (RR 0.13; P=0.04), with similar long-term local recurrence and overall survival compared with wide local excision. Complications were slightly higher but not statistically significant.
Impact: Provides medium-term oncologic safety data supporting broader use of volume-replacement oncoplastic approaches, particularly for larger tumors where cosmesis is at risk.
Clinical Implications: For patients at risk of poor cosmetic outcomes or mastectomy with standard WLE, VR-OPS can increase negative margins and reduce secondary procedures without compromising oncologic safety; patient selection and team experience remain essential.
Key Findings
- Compared 79 VR-OPS vs 80 WLE cases in a retrospective cohort
- VR-OPS associated with significantly more negative margins (RR 0.3638; P=0.01)
- Reduced need for symmetrization surgery after VR-OPS (RR 0.1266; P=0.04)
- No differences in long-term local recurrence (RR 0.79; P=0.81) or overall survival (RR 0.66; P=0.36)
Methodological Strengths
- Direct comparative cohort with seven-year outcomes
- Comprehensive clinicopathological and treatment data extraction
Limitations
- Single-center retrospective design with baseline imbalances (larger, node-positive tumors in VR-OPS)
- Potential selection and confounding biases; lack of patient-reported outcome measures
Future Directions: Prospective multicenter studies with standardized indications and inclusion of patient-reported aesthetic and quality-of-life outcomes; cost-effectiveness analyses.
BACKGROUND: Volume replacement oncoplastic breast surgery (VR-OPS) allows breast conservation for women who would otherwise undergo mastectomy or compromise cosmetic outcomes with wide local excision (WLE). VR-OPS remains understudied in the literature. The aim of this study was to compare 7-year outcomes of VR-OPS METHODS: This is a single-centre retrospective chart review compared VR-OPS (2012-2016) to WLE (2013-2014), analysing clinicopathological, treatment, surgical, and follow-up data. RESULTS: Eighty patients underwent WLE and 79 VR-OPS. No differences in smoking status, cancer type, or grade were observed between the groups. Women in the VR-OPS group were significantly younger, more likely to be node positive, and had larger tumours. Consequently, they received more neo-adjuvant chemotherapy and axillary surgery. VR-OPS resulted in significantly more clear margins [relative risk (RR) =0.3638; 95% confidence interval (CI): 0.1621 to 0.8162; P=0.01], translating to a decreased need for mastectomy (RR =0.2250; 95% CI: 0.0502 to 1.0089; P=0.06). There was also a significant decrease in the need for further breast surgery for symmetrisation after VR-OPS (RR =0.1266; 95% CI: 0.0162 to 0.9887; P=0.04). Although VR-OPS had slightly more post-op complications (RR =1.8228; 95% CI: 0.8982 to 3.6993; P=0.09), this was not statistically significant. Importantly there was no difference in long-term oncological outcomes specifically local-recurrence (RR =0.7949; 95% CI: 0.1152 to 5.484; P=0.81) and overall-survival (RR =0.6551; 95% CI: 0.2633 to 1.6302; P=0.36). CONCLUSIONS: This study observed no significant differences in long-term local recurrence and survival between the VR-OPS and WLE groups. VR-OPS represents an oncologically safe surgical option especially for larger tumours.